NCT06713499

A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

A Phase Ib/II Study to Investigate the Safety、PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.

Conditions

• Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	SHR-1819 injection	SHR-1819 injection.

Timeline

• Start date: 2024-12-18
• Primary completion: 2025-09-01
• Completion: 2025-12-01
• First posted: 2024-12-03
• Last updated: 2025-07-10

Locations

1 site across 1 country: China